These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17205648)

  • 21. Nelfinavir tolerated in HCV patients.
    AIDS Patient Care STDS; 2002 Dec; 16(12):617. PubMed ID: 12881882
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART.
    Kuntzen T; Tural C; Li B; Feldmann G; Kupfer B; Nischalke HD; Clotet B; Sauerbruch T; Rockstroh JK; Spengler U
    AIDS; 2008 Jan; 22(2):203-10. PubMed ID: 18097222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-HIV agents. Should HAART begin right after an HIV diagnosis?
    TreatmentUpdate; 2009; 21(3):2-3. PubMed ID: 19630120
    [No Abstract]   [Full Text] [Related]  

  • 25. Transplanted livers and kidneys for HIV+ people.
    TreatmentUpdate; 2001; 12(12):16-7. PubMed ID: 11570084
    [No Abstract]   [Full Text] [Related]  

  • 26. Hepatitis Cs effect on HIV disease remains elusive despite three new studies.
    Crabb C
    AIDS; 2006 Feb; 20(3):N1-2. PubMed ID: 16439863
    [No Abstract]   [Full Text] [Related]  

  • 27. [Lipid profile for treatment with protease inhibitors].
    Livrozet JM
    Med Mal Infect; 2006 Jul; 36 Suppl 2():S212-7. PubMed ID: 17075999
    [No Abstract]   [Full Text] [Related]  

  • 28. Are deaths due to liver damage becoming more common?
    TreatmentUpdate; 2001; 12(11):5-6. PubMed ID: 11570072
    [No Abstract]   [Full Text] [Related]  

  • 29. Co-infections. Changes to fats and sugar in the blood because of hepatitis C.
    TreatmentUpdate; 2008; 20(3):9-10. PubMed ID: 18661656
    [No Abstract]   [Full Text] [Related]  

  • 30. [Management of adverse effects of hepatitis C treatment].
    González Ballerga E; Fernández N; Losso M
    Acta Gastroenterol Latinoam; 2006 Jun; 36 Suppl 1():S61-4; discussion S74-82. PubMed ID: 16862865
    [No Abstract]   [Full Text] [Related]  

  • 31. Lipodystrophy: a new phenomenon?
    Boyle BA
    AIDS Read; 1999; 9(1):15-7. PubMed ID: 12728877
    [No Abstract]   [Full Text] [Related]  

  • 32. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.
    Riddler SA; Li X; Chu H; Kingsley LA; Dobs A; Evans R; Palella F; Visscher B; Chmiel JS; Sharrett A
    HIV Med; 2007 Jul; 8(5):280-7. PubMed ID: 17561873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of hepatitis C virus coinfection on the risk of lipid abnormalities in a cohort of HIV-1-infected patients after initiation of highly active antiretroviral therapy.
    Di Giambenedetto S; Baldini F; Cingolani A; Tamburrini E; Cauda R; De Luca A
    J Acquir Immune Defic Syndr; 2004 May; 36(1):641-2. PubMed ID: 15097310
    [No Abstract]   [Full Text] [Related]  

  • 34. [Current treatment of HIV infection ].
    Cahn P; Benchetrit G; Laplumé H
    Acta Gastroenterol Latinoam; 2006 Jun; 36 Suppl 1():S41-3; discussion S74-82. PubMed ID: 16862857
    [No Abstract]   [Full Text] [Related]  

  • 35. Liver ultrastructural morphology and mitochondrial DNA levels in HIV/hepatitis C virus coinfection: no evidence of mitochondrial damage with highly active antiretroviral therapy.
    Matsukura M; Chu FF; Au M; Lu H; Chen J; Rietkerk S; Barrios R; Farley JD; Montaner JS; Montessori VC; Walker DC; Côté HC
    AIDS; 2008 Jun; 22(10):1226-9. PubMed ID: 18525271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vertebral fractures in AIDS patients within 6 months from highly active antiretroviral therapy initiation: two case reports.
    Gazzola L; Bini T; Pietrogrande L; Uziel L; Cicconi P; Casana M; Monforte Ad
    AIDS; 2008 May; 22(9):1094-7. PubMed ID: 18520358
    [No Abstract]   [Full Text] [Related]  

  • 37. [HIV therapy: toxic liver injuries caused by protease inhibitors?].
    Kunde K
    Dtsch Med Wochenschr; 2000 Mar; 125(12):A12-3. PubMed ID: 10777343
    [No Abstract]   [Full Text] [Related]  

  • 38. Alpha-fetoprotein and highly active antiretroviral therapy in patients coinfected with HIV-1 and hepatitis C virus.
    Tachikawa N; Kikuchi Y; Masaki N; Saitoh K; Oka S
    Eur J Clin Microbiol Infect Dis; 2001 May; 20(5):364-6. PubMed ID: 11453604
    [No Abstract]   [Full Text] [Related]  

  • 39. Acquired reactive perforating collagenosis induced by indinavir in 2 patients with HIV disease.
    Calista D; Morri M
    Eur J Dermatol; 2008; 18(1):84-5. PubMed ID: 18086600
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.